M&AHealthcareSIGNED
1ST Biotherapeutics and SK Biopharmaceuticals Ink Global License Deal
Value
$314.8M
Acquirer
SK Biopharmaceuticals
Target
1ST-104 (Parkinson's Disease Candidate)
1ST Biotherapeutics and SK Biopharmaceuticals have entered into an exclusive global license agreement for Parkinson's disease candidate '1ST-104'. The deal is valued at up to $314.8 million, including milestones, and involves a separate $2.2 million strategic equity investment.
✦ Meridian Analysis
This licensing agreement represents a significant collaboration in the pharmaceutical sector, focusing on a Parkinson's disease treatment. The substantial value, including potential milestones, indicates the perceived potential of the drug candidate.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.